AllazoHealth’s Technology for Rare Disease Support Programs
More Personalized Patient Support
The pharmaceutical industry spends billions of dollars annually on marketing campaigns and patient support programs (PSPs) aimed at guiding healthcare consumers to start and stay on therapy. But research shows that these initiatives are largely unsuccessful, with low therapy initiation and medication nonadherence, leading to poor health outcomes and high costs. The reason why: although every patient is unique, our industry tends to communicate to them as groups or segments.
Unlike technologies that enable persona-based targeting, AllazoHealth’s AI platform maximizes the impact and efficiency of patient marketing and PSPs by securely and compliantly using identified patient data from both customers’ data sources as well as AllazoHealth’s database of more than 29M patient records to deliver truly personalized interventions at the individual level.
AllazoHealth offers the industry’s most advanced AI for seamlessly integrating, analyzing, and targeting patients for nonadherence risk and personalizing their next-best-action through tailoring the optimal channels, content, timing, and cadence to the individual. AllazoHealth’s AI has been shown to drive 5.5X greater adherence uplift compared to traditional programs and nearly 25% lower spending on interventions.
AllazoHealth is now applying its innovation for patients with rare diseases by partnering with one of the top 10 rare diseases companies in the world. For rare disease therapies, populations are typically small, making effective patient support difficult due to a lack of aggregate-level data. AllazoHealth’s AI technology solves this challenge. In previous case studies for specialty medications, AllazoHealth was able to deliver a 9% increase in initiation rates for an immunology biologic and a 14% increase in days on therapy for a major depressive disorder medication.
